Embla Medical – Presentation of Q4 2024
You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.
Embla Medical will release its Q4 2024 interim report on 5 February 2025. The same day at 11.00, the company’s management will present the results and answer questions in an online live event. Besides the financial results, you can get an update on the recent business and regulatory developments.
For the first nine months of 2024, Embla Medical realized an organic growth of 7% (10% including acquisitions) and an EBITDA margin of 20%. The first nine months of 2024 were in line with the full-year guidance that the company reiterated in connection with the Q3 2024 report. For the full year 2024, Embla Medical expects 6-8% organic growth and an EBITDA margin before special of approx. 20%.
In connection with the Q4 report, we expect that the focus will be on the 2025 guidance. 2025 will be the first full year with the effects of the positive changes to the US reimbursement and the second year in Embla Medical’s Growth’27 strategy period with the ambition of annual revenue growth of 7-10% both organically and through acquisitions, with gradually increasing EBITDA margins.
Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. Embla Medical improves people’s mobility through the delivery of Prosthetics & Neuro Orthotics, Bracing & Supports, and Patient Care.
Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 09.22, 9 January 2025.
